-

Agilent Technologies Announces Pricing of $850 Million of Senior Notes

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the pricing of an underwritten, registered public offering of a series of its senior notes in an aggregate principal amount of $850 million. The offering is being conducted under an automatic shelf registration statement on file with the Securities and Exchange Commission. The notes will mature in March 2031 and will bear interest at an annual rate of 2.300 percent. The offering is expected to close on March 12, 2021, subject to the satisfaction of customary closing conditions.

The estimated net proceeds of the offering are expected to be approximately $841.1 million. Agilent intends to use the net proceeds from the offering to fund the redemption of its 3.20% senior notes due 2022 (the “2022 notes”), to pay down borrowings under its commercial paper program and for general corporate purposes.

Barclays Capital Inc., Citigroup Global Markets Inc. and J.P. Morgan Securities LLC are acting as joint book-running managers.

Copies of the prospectus supplement and the accompanying prospectus relating to the offering can be obtained from:

Barclays Capital Inc.
c/o Broadridge Financial Solutions
1155 Long Island Avenue
Edgewood, NY 11717
Email: barclaysprospectus@broadridge.com
Telephone: 1-888-603-5847

Citigroup Global Markets Inc.
c/o Broadridge Financial Solutions
1155 Long Island Avenue
Edgewood, New York 11717
Email: prospectus@citi.com
Telephone: 1-800-831-9146

J.P. Morgan Securities LLC
c/o Broadridge Financial Solutions
Attn: Prospectus Department
1155 Long Island Avenue
Edgewood, NY 11717
Telephone: 1-866-803-9204

Electronic copies of the prospectus supplement and accompanying prospectus are or will be available for free by visiting EDGAR on the Securities and Exchange Commission website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release also does not constitute a notice of redemption under the indenture governing the 2022 notes.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the federal securities laws, including with respect to the closing of Agilent’s senior notes offering and the anticipated use of the net proceeds therefrom, including the redemption of its 2022 notes. Forward-looking statements are typically identified by words or phrases such as “will,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “forecast,” and other words and terms of similar meaning. These statements are subject to significant risks and uncertainties, including, without limitation, risks and uncertainties related to economic, market or business conditions and satisfaction of customary closing conditions related to the public offering. No assurance can be given that the securities offering discussed above will be consummated on the terms described or at all. Except as required by law, Agilent expressly disclaims any obligation to publicly revise any forward-looking statements contained in this news release to reflect the occurrence of events after the date of this news release.

Contacts

Investor Contact:
Ankur Dhingra
+1 408 345 8948
ankur_dhingra@agilent.com

Media Contact:
Tom Beermann
+1 408-553-2914
tom.beermann@agilent.com

Agilent Technologies, Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Summary
Agilent Technologies announces pricing of $850 million of senior notes.
Release Versions

Contacts

Investor Contact:
Ankur Dhingra
+1 408 345 8948
ankur_dhingra@agilent.com

Media Contact:
Tom Beermann
+1 408-553-2914
tom.beermann@agilent.com

More News From Agilent Technologies, Inc.

Agilent to Participate in J.P. Morgan U.S. All Stars Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference. The event is scheduled for 10 a.m. BST on Wednesday, Sept. 23, 2026, in London. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader...

Agilent Announces Retirement of Board Chair Koh Boon Hwee, Appointment of Glenn Boehnlein to Board of Directors

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Koh Boon Hwee, independent chair of the company's board of directors, retired from the board effective Sept. 4, 2026, following more than two decades of service as a director. Koh joined Agilent’s board in 2003 and served as independent chair from 2017 until his retirement.He chaired the board’s Executive Committee and Nominating and Corporate Governance Committee. Koh brought extensive international l...

Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the U.S. launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner, following FDA clearance. This launch underscores Agilent’s ongoing commitment to digital pathology, broadening its portfolio to address the increasing demand for high-throughput solutions in clinical laboratories.Pathology laboratories continue to face increasing pressure to improve diagnostic efficiency...
Back to Newsroom